Tag: Eisai Inc.

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsEisai Inc.

Stardog Appoints Sara Golbourn as Chief Revenue Officer to Scale the Enterprise Answer Engine

URBAN SCIENCE AND THE HARRIS POLL RELEASE 2025 AUTOMOTIVE DATA AND INSIGHTS KEY FINDINGS

Somatus Surpasses 500,000 Patients Actively Under Management Across All 50 States and DC

Tag: Eisai Inc.

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us